Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?

Research output: Contribution to journalArticle

Abstract

Since over 70% of patients with non-small cell lung cancer (NSCLC) have advanced (locally advanced or metastatic) disease, the majority of NSCLC patients might benefit from chemotherapy. During the past decade, a number of new agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, and topotecan) have been found to be effective against lung cancer. These agents have been combined with cisplatin, carboplatin, and nonplatinum drugs to treat NSCLC. They, in general, produce median survival times of 8-10 months and 1- and 2-year survival rates of 35%-40% and 10%-15%, respectively. Based on this review, there is not a preferred combination chemotherapy regimen to treat advanced NSCLC patients. However, there are a number of different regimens from which to choose.

Original languageEnglish (US)
Pages (from-to)226-233
Number of pages8
JournalOncologist
Volume7
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Combination Drug Therapy
Non-Small Cell Lung Carcinoma
irinotecan
docetaxel
gemcitabine
Topotecan
Carboplatin
Paclitaxel
Cisplatin
Lung Neoplasms
Survival Rate
Drug Therapy
Survival
Pharmaceutical Preparations

Keywords

  • Combination chemotherapy
  • Metastatic non-small cell lung cancer
  • Phase III studies

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer? / Ettinger, David S.

In: Oncologist, Vol. 7, No. 3, 2002, p. 226-233.

Research output: Contribution to journalArticle

@article{c465db55bd90451ebd5349931a29063e,
title = "Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?",
abstract = "Since over 70{\%} of patients with non-small cell lung cancer (NSCLC) have advanced (locally advanced or metastatic) disease, the majority of NSCLC patients might benefit from chemotherapy. During the past decade, a number of new agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, and topotecan) have been found to be effective against lung cancer. These agents have been combined with cisplatin, carboplatin, and nonplatinum drugs to treat NSCLC. They, in general, produce median survival times of 8-10 months and 1- and 2-year survival rates of 35{\%}-40{\%} and 10{\%}-15{\%}, respectively. Based on this review, there is not a preferred combination chemotherapy regimen to treat advanced NSCLC patients. However, there are a number of different regimens from which to choose.",
keywords = "Combination chemotherapy, Metastatic non-small cell lung cancer, Phase III studies",
author = "Ettinger, {David S}",
year = "2002",
doi = "10.1634/theoncologist.7-3-226",
language = "English (US)",
volume = "7",
pages = "226--233",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?

AU - Ettinger, David S

PY - 2002

Y1 - 2002

N2 - Since over 70% of patients with non-small cell lung cancer (NSCLC) have advanced (locally advanced or metastatic) disease, the majority of NSCLC patients might benefit from chemotherapy. During the past decade, a number of new agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, and topotecan) have been found to be effective against lung cancer. These agents have been combined with cisplatin, carboplatin, and nonplatinum drugs to treat NSCLC. They, in general, produce median survival times of 8-10 months and 1- and 2-year survival rates of 35%-40% and 10%-15%, respectively. Based on this review, there is not a preferred combination chemotherapy regimen to treat advanced NSCLC patients. However, there are a number of different regimens from which to choose.

AB - Since over 70% of patients with non-small cell lung cancer (NSCLC) have advanced (locally advanced or metastatic) disease, the majority of NSCLC patients might benefit from chemotherapy. During the past decade, a number of new agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, and topotecan) have been found to be effective against lung cancer. These agents have been combined with cisplatin, carboplatin, and nonplatinum drugs to treat NSCLC. They, in general, produce median survival times of 8-10 months and 1- and 2-year survival rates of 35%-40% and 10%-15%, respectively. Based on this review, there is not a preferred combination chemotherapy regimen to treat advanced NSCLC patients. However, there are a number of different regimens from which to choose.

KW - Combination chemotherapy

KW - Metastatic non-small cell lung cancer

KW - Phase III studies

UR - http://www.scopus.com/inward/record.url?scp=0036076240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036076240&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.7-3-226

DO - 10.1634/theoncologist.7-3-226

M3 - Article

C2 - 12065795

AN - SCOPUS:0036076240

VL - 7

SP - 226

EP - 233

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 3

ER -